1. Punga A.R. et al. Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders//Lancet Neurol. Elsevier, 2022. Vol. 21, N 2. P. 176 - 188.

2. Verschuuren J.J.G.M. et al. Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders//Lancet Neurol. Elsevier, 2022. Vol. 21, N 2. P. 189 - 202.

3. Mantegazza R., Bernasconi P., Cavalcante P. Myasthenia gravis: from autoantibodies to therapy. 2018. P. 517 - 525.

4. Cetin H., Vincent A. Pathogenic Mechanisms and Clinical Correlations in Autoimmune Myasthenic Syndromes//Semin. Neurol. 2018. Vol. 38, N 3. P. 344 - 354.

5. Zieda A. et al. A nationwide epidemiological study of myasthenia gravis in Latvia//Eur. J. Neurol. 2018. Vol. 25, N 3. P. 519 - 526.

6. Meriggioli M.N., Sanders D.B. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity.//Lancet. Neurol. England, 2009. Vol. 8, N 5. P. 475 - 490.

7. Zhang J. et al. AChRAb and MuSKAb double-seropositive myasthenia gravis: a distinct subtype?//Neurol. Sci. Off. J. Ital. Neurol. Soc. Ital. Soc. Clin. Neurophysiol. Italy, 2021. Vol. 42, N 3. P. 863 - 869.

8. Taioli E. et al. Comparison of Conservative Treatment and Thymectomy on Myasthenia Gravis Outcome.//Ann. Thorac. Surg. Netherlands, 2016. Vol. 102, N 6. P. 1805 - 1813.

9. Vakrakou A.G. et al. Immunotherapies in MuSK-positive Myasthenia Gravis; an IgG4 antibody-mediated disease.//Front. Immunol. Switzerland, 2023. Vol. 14. P. 1212757.

10. Guptill J.T., Sanders D.B., Evoli A. Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts.//Muscle Nerve. United States, 2011. Vol. 44, N 1. P. 36 - 40.

11. Carr A.S. et al. A systematic review of population based epidemiological studies in Myasthenia Gravis.//BMC Neurol. England, 2010. Vol. 10. P. 46.

12. Romanova T. V. Samara epidemiological research of myasthenia gravis//Saratov J. Med. Sci. Res. 2012. Vol. 8, N 1. P. 91 - 95.

13. KHATKHE Y.A. et al. Epidemiological Features of Myasthenia Gravis//Kuban. nauchnyj Med. Vestn. 2018. Vol. 25, N 1. P. 195 - 198.

14. Боев В.M. et al. Экологические аспекты миастении в Оренбургской области//Гигиена и санитария. Федеральное бюджетное учреждение науки "Федеральный научный центр гигиены им..., 2002. N 5. P. 46 - 49.

15. Бондаренко Л.А., Пенина Г.О. Эпидемиология, клинико-функциональные характеристики и качество жизни больных миастенией жителей европейского севера//Международный неврологический журнал. Гражданин Украины Заславский Александр Юрьевич, 2009. N 1. P. 71 - 75.

16. Bubuioc A.M. et al. The epidemiology of myasthenia gravis//J. Med. Life. 2021. Vol. 14, N 1. P. 7 - 16.

17. Stetefeld H., Schroeter M. SOP myasthenic crisis.//Neurol. Res. Pract. England, 2019. Vol. 1. P. 19.

18. O'Connell K., Ramdas S., Palace J. Management of Juvenile Myasthenia Gravis.//Front. Neurol. Switzerland, 2020. Vol. 11. P. 743.

19. Heckmann J.M. et al. The Epidemiology and Phenotypes of Ocular Manifestations in Childhood and Juvenile Myasthenia Gravis: A Review.//Front. Neurol. 2022. Vol. 13. P. 834212.

20. Jaretzki A. 3rd et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America.//Neurology. United States, 2000. Vol. 55, N 1. P. 16 - 23.

21. Gilhus N.E., Verschuuren J.J. Myasthenia gravis: subgroup classification and therapeutic strategies.//Lancet. Neurol. England, 2015. Vol. 14, N 10. P. 1023 - 1036.

22. Кузин М.И., Гехт Б.М., Поздняков О.М. Миастения. Открытое акционерное общество Издательство Медицина, 1996.

23. Санадзе А.Г. Миастения и миастенические синдромы. Литтерра, 2012.

24. Pasnoor M. et al. Clinical findings in MuSK-antibody positive myasthenia gravis: a U.S. experience.//Muscle Nerve. United States, 2010. Vol. 41, N 3. P. 370 - 374.

25. Zhang C. et al. Mortality of myasthenia gravis: a national population-based study in China. 2023. P. 1 - 11.

26. Gupta A. et al. Remission And relapse of myasthenia gravis on long-term azathioprine: An ambispective study.//Muscle Nerve. United States, 2016. Vol. 54, N 3. P. 405 - 412.

27. Narayanaswami P. et al. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update.//Neurology. United States, 2021. Vol. 96, N 3. P. 114 - 122.

28. Estephan E. de P., Baima J.P.S., Zambon A.A. Myasthenia gravis in clinical practice.//Arq. Neuropsiquiatr. Germany, 2022. Vol. 80, N 5 Suppl 1. P. 257 - 265.

29. Torre S.M., Molinero I.G., An update on myasthenia gravis//Semergen. 2018. Vol. 44, N 5. P. 351 - 354.

30. Халмурзина А.Н. et al. Анализ клинических проявлений и диагностики миастении с дебютом в пожилом возрасте//Нервно-мышечные болезни. Общество с ограниченной ответственностью "Издательский дом "АБВ-пресс", 2020. Vol. 10, N 1. P. 53 - 63.

31. Hayashi M. Childhood myasthenia gravis in Japan: Pathophysiology and treatment options//Clin. Exp. Neuroimmunol. Wiley Online Library, 2023. Vol. 14, N 4. P. 185 - 194.

32. Cejvanovic S., Vissing J. Muscle strength in myasthenia gravis.//Acta Neurol. Scand. Denmark, 2014. Vol. 129, N 6. P. 367 - 373.

33. Sanders D.B. et al. The Duke myasthenia gravis clinic registry: I. Description and demographics.//Muscle Nerve. United States, 2021. Vol. 63, N 2. P. 209 - 216.

34. Varghese T. et al. D-Penicillamine induced myasthenia gravis.//Neurosciences (Riyadh). Saudi Arabia, 2002. Vol. 7, N 4. P. 293 - 295.

35. Haugh A.M., Probasco J.C., Johnson D.B. Neurologic complications of immune checkpoint inhibitors.//Expert Opin. Drug Saf. England, 2020. Vol. 19, N 4. P. 479 - 488.

36. Safa H. et al. Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature.//J. Immunother. cancer. England, 2019. Vol. 7, N 1. P. 319.

37. Gilhus N.E. et al. Myasthenia gravis.//Nat. Rev. Dis. Prim. England, 2019. Vol. 5, N 1. P. 30.

38. Drachman D.B. Myasthenia Gravis.//Semin. Neurol. United States, 2016. Vol. 36, N 5. P. 419 - 424.

39. Prior D.E. et al. Developing outcome measures of disease activity in pediatric myasthenia.//Muscle Nerve. United States, 2021. Vol. 63, N 5. P. 751 - 757.

40. Yoganathan K. et al. Bedside and laboratory diagnostic testing in myasthenia.//J. Neurol. Germany, 2022. Vol. 269, N 6. P. 3372 - 3384.

41. Citirak G. et al. Effect of Gender, Disease Duration and Treatment on Muscle Strength in Myasthenia Gravis.//PLoS One. United States, 2016. Vol. 11, N 10. P. e0164092.

42. Mishra A.K., Varma A. Myasthenia Gravis: A Systematic Review.//Cureus. United States, 2023. Vol. 15, N 12. P. e50017.

43. Rodolico C. et al. MuSK-Associated Myasthenia Gravis: Clinical Features and Management//Front. Neurol. 2020. Vol. 11, N July. P. 1 - 5.

44. Gao F. et al. Clinical features of patients with Myasthenia gravis from the Henan province, China.//Muscle Nerve. United States, 2016. Vol. 53, N 5. P. 711 - 716.

45. Gilhus N.E. et al. Generalized myasthenia gravis with acetylcholine receptor antibodies: A guidance for treatment//Eur. J. Neurol. 2024. Vol. 31, N 5. P. 1 - 13.

46. Li Y., Peng Y., Yang H. Serological diagnosis of myasthenia gravis and its clinical significance.//Ann. Transl. Med. China, 2023. Vol. 11, N 7. P. 290.

47. Lazaridis K., Tzartos S.J. Autoantibody Specificities in Myasthenia Gravis; Implications for Improved Diagnostics and Therapeutics.//Front. Immunol. Switzerland, 2020. Vol. 11. P. 212.

48. Pasnoor M. et al. Diagnosis of Myasthenia Gravis.//Neurol. Clin. United States, 2018. Vol. 36, N 2. P. 261 - 274.

49. Gilhus N.E. et al. Myasthenia gravis - autoantibody characteristics and their implications for therapy.//Nat. Rev. Neurol. England, 2016. Vol. 12, N 5. P. 259 - 268.

50. Berrih-Aknin S., Le Panse R. Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms.//J. Autoimmun. England, 2014. Vol. 52. P. 90 - 100.

51. Benatar M. A systematic review of diagnostic studies in myasthenia gravis.//Neuromuscul. Disord. England, 2006. Vol. 16, N 7. P. 459 - 467.

52. Huang C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.//Lancet (London, England). 2020. Vol. 395, N 10223. P. 497 - 506.

53. Maddison P. et al. False-positive acetylcholine receptor antibody results in patients without myasthenia gravis.//J. Neuroimmunol. Netherlands, 2019. Vol. 332. P. 69 - 72.

54. Tsonis A.I. et al. MuSK autoantibodies in myasthenia gravis detected by cell based assay--A multinational study.//J. Neuroimmunol. Netherlands, 2015. Vol. 284. P. 10 - 17.

55. Rodriguez Cruz P.M. et al. Use of cell-based assays in myasthenia gravis and other antibody-mediated diseases.//Exp. Neurol. United States, 2015. Vol. 270. P. 66 - 71.

56. Vinciguerra C. et al. Diagnosis and Management of Seronegative Myasthenia Gravis: Lights and Shadows.//Brain Sci. Switzerland, 2023. Vol. 13, N 9.

57. Zisimopoulou P. et al. A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis.//J. Autoimmun. England, 2014. Vol. 52. P. 139 - 145.

58. Gasperi C. et al. Anti-agrin autoantibodies in myasthenia gravis.//Neurology. United States, 2014. Vol. 82, N 22. P. 1976 - 1983.

59. Ciafaloni E. Myasthenia Gravis and Congenital Myasthenic Syndromes.//Continuum (Minneap. Minn). United States, 2019. Vol. 25, N 6. P. 1767 - 1784.

60. Ohno K. et al. Clinical and Pathologic Features of Congenital Myasthenic Syndromes Caused by 35 Genes-A Comprehensive Review.//Int. J. Mol. Sci. Switzerland, 2023. Vol. 24, N 4.

61. Electromyography and Neuromuscular Disorders: Clinical-Electrodiagnostic-Ultrasound Correlations, Fourth Edition.//J. Clin. Neurophysiol. Off. Publ. Am. Electroencephalogr. Soc. United States, 2021. Vol. 38, N 4. P. e19.

62. Chiou Tan F.Y., Gilchrist J.M. Repetitive nerve stimulation and single fiber electromyography in the evaluation of patients with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome: Review of recent literature//Muscle Nerve. Wiley Online Library, 2015. Vol. 52, N 3. P. 455 - 462.

63. Санадзе А.Г., Касаткина Л.Ф. Клиническая электромиография для практических неврологов//М. ГЭОТАР-Медиа. 2008. P. 24 - 25.

64. Касаткина Л.Ф., Гильванова О.В. Электромиографические методы исследования в диагностике нервно-мышечных заболеваний//М. Медика. 2010. Vol. 416.

65. Тумуров Д.А., Санадзе А.Г. Декремент амплитуды М-ответа при низкочастотной стимуляции мышц больных миастенией и миастеническим синдромом Ламберта-Итона//Журнал неврологии и психиатрии им. С.С. Корсакова. Издательство 'Медиа Сфера', 2017. Vol. 117, N 2. P. 93 - 96.

66. Guerrero G.O. et al. Timing of Decremental Response During Repetitive Nerve Stimulation in Myasthenia Gravis//RRNMF Neuromuscul. J. 2022. Vol. 3, N 1. P. 8 - 12.

67. Howard J.F.J. Electrodiagnosis of disorders of neuromuscular transmission.//Phys. Med. Rehabil. Clin. N. Am. United States, 2013. Vol. 24, N 1. P. 169 - 192.

68. Tomschik M. et al. The diagnostic and prognostic utility of repetitive nerve stimulation in patients with myasthenia gravis.//Sci. Rep. England, 2023. Vol. 13, N 1. P. 2985.

69. Kongsaengdao S. et al. Electrophysiological diagnosis and patterns of response to treatment of botulism with neuromuscular respiratory failure.//Muscle Nerve. United States, 2009. Vol. 40, N 2. P. 271 - 278.

70. Padua L. et al. Reliability of SFEMG in diagnosing myasthenia gravis: sensitivity and specificity calculated on 100 prospective cases.//Clin. Neurophysiol. Off. J. Int. Fed. Clin. Neurophysiol. Netherlands, 2014. Vol. 125, N 6. P. 1270 - 1273.

71. , Sanders D.B. Jitter recordings with concentric needle electrodes.//Muscle Nerve. United States, 2009. Vol. 40, N 3. P. 331 - 339.

72. Sarrigiannis P.G. et al. Single-fiber EMG with a concentric needle electrode: validation in myasthenia gravis.//Muscle Nerve. United States, 2006. Vol. 33, N 1. P. 61 - 65.

73. Larson S.T., Wilbur J. Muscle Weakness in Adults: Evaluation and Differential Diagnosis.//Am. Fam. Physician. United States, 2020. Vol. 101, N 2. P. 95 - 108.

74. Juel V.C. Clinical neurophysiology of neuromuscular junction disease.//Handb. Clin. Neurol. Netherlands, 2019. Vol. 161. P. 291 - 303.

75. Li H.-R. et al. Comparison between CT and MRI in the Diagnostic Accuracy of Thymic Masses.//J. Cancer. Australia, 2019. Vol. 10, N 14. P. 3208 - 3213.

76. Strange C.D. et al. Imaging Evaluation of Thymoma and Thymic Carcinoma.//Front. Oncol. Switzerland, 2021. Vol. 11. P. 810419.

77. Carter B.W. et al. Approaching the patient with an anterior mediastinal mass: a guide for radiologists.//J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer. United States, 2014. Vol. 9, N 9 Suppl 2. P. S110-8.

78. Tomiyama N. et al. Anterior mediastinal tumors: diagnostic accuracy of CT and MRI.//Eur. J. Radiol. Ireland, 2009. Vol. 69, N 2. P. 280 - 288.

79. Benveniste M.F.K. et al. Role of imaging in the diagnosis, staging, and treatment of thymoma.//Radiogr. a Rev. Publ. Radiol. Soc. North Am. Inc. United States, 2011. Vol. 31, N 7. P. 1843 - 1847.

80. Rousseff R.T. Diagnosis of Myasthenia Gravis.//J. Clin. Med. Switzerland, 2021. Vol. 10, N 8.

81. Sciacca G. et al. Clinical and CN-SFEMG evaluation of neostigmine test in myasthenia gravis.//Neurol. Sci. Off. J. Ital. Neurol. Soc. Ital. Soc. Clin. Neurophysiol. Italy, 2018. Vol. 39, N 2. P. 341 - 345.

82. Patil S.A. et al. Diagnosis of myasthenia gravis: Comparison of anti-nicotinic acetyl choline receptor antibodies, repetitive nerve stimulation and Neostigmine tests at a tertiary neuro care centre in India, a ten year study.//J. Neuroimmunol. Netherlands, 2016. Vol. 292. P. 81 - 84.

83. Proudman W. et al. The Icepack Test in the Diagnosis of Myasthenia Gravis with Ocular Features: A Systematic Review of Diagnostic Accuracy, Technique, and Economic Utility.//Semin. Ophthalmol. England, 2023. Vol. 38, N 7. P. 679 - 685.

84. Fakiri M.O. et al. Accuracy of the ice test in the diagnosis of myasthenia gravis in patients with ptosis.//Muscle Nerve. United States, 2013. Vol. 48, N 6. P. 902 - 904.

85. Giannoccaro M.P. et al. Comparison of ice pack test and single-fiber EMG diagnostic accuracy in patients referred for myasthenic ptosis.//Neurology. United States, 2020. Vol. 95, N 13. P. e1800 - e1806.

86. Alhaidar M.K. et al. Current Treatment of Myasthenia Gravis.//J. Clin. Med. Switzerland, 2022. Vol. 11, N 6.

87. Skeie G.O. et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders.//Eur. J. Neurol. England, 2010. Vol. 17, N 7. P. 893 - 902.

88. Sussman J. et al. Myasthenia gravis: Association of British Neurologists' management guidelines.//Pract. Neurol. England, 2015. Vol. 15, N 3. P. 199 - 206.

89. Mittal M.K. et al. Ocular myasthenia gravis in an academic neuro-ophthalmology clinic: clinical features and therapeutic response.//J. Clin. Neuromuscul. Dis. United States, 2011. Vol. 13, N 1. P. 46 - 52.

90. Arroyo H.A. [Treatment of juvenile myasthenia gravis].//Medicina (B. Aires). Argentina, 2019. Vol. 79 Suppl 3. P. 71 - 76.

91. Wiendl H. et al. Guideline for the management of myasthenic syndromes.//Ther. Adv. Neurol. Disord. England, 2023. Vol. 16. P. 17562864231213240.

92. Evoli A. et al. Long-term results of corticosteroid therapy in patients with myasthenia gravis.//Eur. Neurol. Switzerland, 1992. Vol. 32, N 1. P. 37 - 43.

93. Kanai T. et al. Predictive score for oral corticosteroid-induced initial worsening of seropositive generalized myasthenia gravis.//J. Neurol. Sci. Netherlands, 2019. Vol. 396. P. 8 - 11.

94. Farmakidis C. et al. Treatment of Myasthenia Gravis.//Neurol. Clin. United States, 2018. Vol. 36, N 2. P. 311 - 337.

95. Benatar M. et al. Efficacy of prednisone for the treatment of ocular myasthenia (EPITOME): A randomized, controlled trial.//Muscle Nerve. United States, 2016. Vol. 53, N 3. P. 363 - 369.

96. Бардаков С.Н. et al. Современные представления о рациональной диагностике и лечении приобретенной миастении. Часть 1: диагностика//Ученые записки СПбГМУ им. ИП Павлова. Федеральное государственное бюджетное образовательное учреждение высшего..., 2016. Vol. 23, N 2. P. 20 - 26.

97. Kerty E. et al. EFNS/ENS Guidelines for the treatment of ocular myasthenia.//Eur. J. Neurol. England, 2014. Vol. 21, N 5. P. 687 - 693.

98. Fonseca V., Havard C.W. Long term treatment of myasthenia gravis with azathioprine.//Postgrad. Med. J. England, 1990. Vol. 66, N 772. P. 102 - 105.

99. Chiang L.M., Darras B.T., Kang P.B. Juvenile myasthenia gravis.//Muscle Nerve. United States, 2009. Vol. 39, N 4. P. 423 - 431.

100. Chaudhry V. et al. Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases.//Neurology. United States, 2001. Vol. 56, N 1. P. 94 - 96.

101. Hehir M.K. et al. Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: outcomes in 102 patients.//Muscle Nerve. United States, 2010. Vol. 41, N 5. P. 593 - 598.

102. Menon D., Bril V. Pharmacotherapy of Generalized Myasthenia Gravis with Special Emphasis on Newer Biologicals.//Drugs. New Zealand, 2022. Vol. 82, N 8. P. 865 - 887.

103. Heatwole C., Ciafaloni E. Mycophenolate mofetil for myasthenia gravis: a clear and present controversy.//Neuropsychiatr. Dis. Treat. New Zealand, 2008. Vol. 4, N 6. P. 1203 - 1209.

104. Coscia L.A. et al. Update on the Teratogenicity of Maternal Mycophenolate Mofetil.//J. Pediatr. Genet. Germany, 2015. Vol. 4, N 2. P. 42 - 55.

105. Lavrnic D. et al. Cyclosporine in the treatment of myasthenia gravis.//Acta Neurol. Scand. Denmark, 2005. Vol. 111, N 4. P. 247 - 252.

106. Tindall R.S. et al. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis.//N. Engl. J. Med. United States, 1987. Vol. 316, N 12. P. 719 - 724.

107. Tindall R.S. et al. A clinical therapeutic trial of cyclosporine in myasthenia gravis.//Ann. N. Y. Acad. Sci. United States, 1993. Vol. 681. P. 539 - 551.

108. Щербакова Н.И. et al. Роль циклоспорина в лечении тяжелых форм миастении: клиническое исследование 51 больного//Анналы клинической и экспериментальной неврологии. Федеральное государственное бюджетное научное учреждение "Научный центр..., 2013. Vol. 7, N 2. P. 4 - 10.

109. Souayah N., Khella S.L. Low dose of cyclosporine in myasthenia gravis//J. Clin. Neuromuscul. Dis. LWW, 2006. Vol. 8, N 2. P. 75 - 79.

110. Lee J.-I., Jander S. Myasthenia gravis: recent advances in immunopathology and therapy.//Expert Rev. Neurother. England, 2017. Vol. 17, N 3. P. 287 - 299.

111. Melzer N. et al. Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society.//J. Neurol. 2016. Vol. 263, N 8. P. 1473 - 1494.

112. Heckmann J.M. et al. A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis.//BMC Neurol. England, 2011. Vol. 11. P. 97.

113. Rodolico C. et al. Methotrexate as a Steroid-Sparing Agent in Myasthenia Gravis: A Preliminary Retrospective Study.//J. Clin. Neuromuscul. Dis. United States, 2021. Vol. 23, N 2. P. 61 - 65.

114. Yoshikawa H. et al. Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis.//J. Neurol. Neurosurg. Psychiatry. England, 2011. Vol. 82, N 9. P. 970 - 977.

115. Nagane Y. et al. Efficacy of low-dose FK506 in the treatment of Myasthenia gravis--a randomized pilot study.//Eur. Neurol. Switzerland, 2005. Vol. 53, N 3. P. 146 - 150.

116. Zhou L. et al. Tacrolimus in the treatment of myasthenia gravis in patients with an inadequate response to glucocorticoid therapy: randomized, double-blind, placebo-controlled study conducted in China.//Ther. Adv. Neurol. Disord. England, 2017. Vol. 10, N 9. P. 315 - 325.

117. Fan Z. et al. Favorable Effects of Tacrolimus Monotherapy on Myasthenia Gravis Patients.//Front. Neurol. Switzerland, 2020. Vol. 11. P. 594152.

118. Wang G. et al. Treatment of juvenile myasthenia gravis with tacrolimus: A cohort study.//Eur. J. Neurol. England, 2024. Vol. 31, N 12. P. e16466.

119. Wang L. et al. Efficacy and safety of tacrolimus for myasthenia gravis: a systematic review and meta-analysis.//J. Neurol. Germany, 2017. Vol. 264, N 11. P. 2191 - 2200.

120. Kim Y.H., Shin H.Y., Kim S.M. Long-Term Safety and Efficacy of Tacrolimus in Myasthenia Gravis.//Yonsei Med. J. Korea (South), 2019. Vol. 60, N 7. P. 633 - 639.

121. Kanai T. et al. Adequate tacrolimus concentration for myasthenia gravis treatment.//Eur. J. Neurol. England, 2017. Vol. 24, N 2. P. 270 - 275.

122. van Gelder T. Drug interactions with tacrolimus.//Drug Saf. New Zealand, 2002. Vol. 25, N 10. P. 707 - 712.

123. Gajdos P. et al. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group.//Ann. Neurol. United States, 1997. Vol. 41, N 6. P. 789 - 796.

124. Barth D. et al. Comparison of IVIg and PLEX in patients with myasthenia gravis.//Neurology. United States, 2011. Vol. 76, N 23. P. 2017 - 2023.

125. Murthy J.M.K. et al. Myasthenic crisis: clinical features, complications and mortality.//Neurol. India. India, 2005. Vol. 53, N 1. P. 37 - 40; discussion 40.

126. Qureshi A.I. et al. Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis.//Neurology. United States, 1999. Vol. 52, N 3. P. 629 - 632.

127. Trikha I. et al. Comparative efficacy of low dose, daily versus alternate day plasma exchange in severe myasthenia gravis: a randomised trial.//J. Neurol. Germany, 2007. Vol. 254, N 8. P. 989 - 995.

128. Zinman L., Ng E., Bril V. IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial.//Neurology. United States, 2007. Vol. 68, N 11. P. 837 - 841.

129. Gajdos P., Chevret S., Toyka K. V. Intravenous immunoglobulin for myasthenia gravis.//Cochrane database Syst. Rev. England, 2012. Vol. 12, N 12. P. CD002277.

130. Gajdos P. et al. Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: a randomized double-blind clinical trial.//Arch. Neurol. United States, 2005. Vol. 62, N 11. P. 1689 - 1693.

131. Kareva L. et al. Adverse Reactions to Intravenous Immunoglobulins - Our Experience.//Open access Maced. J. Med. Sci. North Macedonia, 2018. Vol. 6, N 12. P. 2359 - 2362.

132. Guo Y. et al. Adverse Effects of Immunoglobulin Therapy.//Front. Immunol. Switzerland, 2018. Vol. 9. P. 1299.

133. Herrmann D.N., Carney P.R., Wald J.J. Juvenile myasthenia gravis: treatment with immune globulin and thymectomy.//Pediatr. Neurol. United States, 1998. Vol. 18, N 1. P. 63 - 66.

134. Selcen D. et al. High-dose intravenous immunoglobulin therapy in juvenile myasthenia gravis.//Pediatr. Neurol. United States, 2000. Vol. 22, N 1. P. 40 - 43.

135. Liew W.K.M. et al. Comparison of plasmapheresis and intravenous immunoglobulin as maintenance therapies for juvenile myasthenia gravis.//JAMA Neurol. United States, 2014. Vol. 71, N 5. P. 575 - 580.

136. Howard J.F.J. et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.//Lancet. Neurol. England, 2017. Vol. 16, N 12. P. 976 - 986.

137. Howard J.F.J. et al. A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis.//Muscle Nerve. United States, 2013. Vol. 48, N 1. P. 76 - 84.

138. Tokuyasu D. et al. Real-world experience with eculizumab and switching to ravulizumab for generalized myasthenia gravis.//Ann. Clin. Transl. Neurol. United States, 2024. Vol. 11, N 5. P. 1338 - 1346.

139. Mantegazza R. et al. Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension.//Neurology. United States, 2021. Vol. 96, N 4. P. e610 - e618.

140. Monteleone J.P.R. et al. Eculizumab Pharmacokinetics and Pharmacodynamics in Patients With Generalized Myasthenia Gravis.//Front. Neurol. Switzerland, 2021. Vol. 12. P. 696385.

141. Vu T. et al. Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis.//NEJM Evid. United States, 2022. Vol. 1, N 5. P. EVIDoa2100066.

142. Meisel A. et al. Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension.//J. Neurol. Germany, 2023. Vol. 270, N 8. P. 3862 - 3875.

143. Howard J.F.J. et al. Efficacy of ravulizumab in patients with generalized myasthenia gravis by time from diagnosis: A post hoc subgroup analysis of the CHAMPION MG study.//Muscle Nerve. United States, 2024. Vol. 69, N 5. P. 556 - 565.

144. Lee J.W. et al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study.//Blood. United States, 2019. Vol. 133, N 6. P. 530 - 539.

145. Tandan R. et al. Rituximab treatment of myasthenia gravis: A systematic review.//Muscle Nerve. United States, 2017. Vol. 56, N 2. P. 185 - 196.

146. Iorio R. et al. Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis.//J. Neurol. Germany, 2015. Vol. 262, N 5. P. 1115 - 1119.

147. Li T. et al. Efficacy and safety of different dosages of rituximab for refractory generalized AChR myasthenia gravis: A meta-analysis.//J. Clin. Neurosci. Off. J. Neurosurg. Soc. Australas. Scotland, 2021. Vol. 85. P. 6 - 12.

148. Levin A.S. et al. Reactions to Rituximab in an Outpatient Infusion Center: A 5-Year Review.//J. allergy Clin. Immunol. Pract. United States, 2017. Vol. 5, N 1. P. 107 - 113.e1.

149. Fouda G.E., Bavbek S. Rituximab Hypersensitivity: From Clinical Presentation to Management.//Front. Pharmacol. Switzerland, 2020. Vol. 11. P. 572863.

150. Kanth K.M., Solorzano G.E., Goldman M.D. PML in a patient with myasthenia gravis treated with multiple immunosuppressing agents.//Neurology. Clinical practice. United States, 2016. Vol. 6, N 2. P. e17 - e19.

151. Molimard A. et al. Rituximab Therapy in the Treatment of Juvenile Myasthenia Gravis: The French Experience.//Neurology. United States, 2022. Vol. 98, N 23. P. e2368 - e2376.

152. Koul R. et al. Rituximab Treatment in Myasthaenia Gravis: Report of two paediatric cases.//Sultan Qaboos Univ. Med. J. Oman, 2018. Vol. 18, N 2. P. e223 - e227.

153. Wylam M.E. et al. Successful treatment of refractory myasthenia gravis using rituximab: a pediatric case report.//J. Pediatr. United States, 2003. Vol. 143, N 5. P. 674 - 677.

154. Weger S., Appendino J.P., Clark I.H. Longstanding and Refractory Anti-Muscle Specific Tyrosine Kinase Antibody-Associated Myasthenia Gravis (Anti-MuSK-MG) in a Child Successfully Treated with Rituximab.//J. Binocul. Vis. Ocul. Motil. United States, 2019. Vol. 69, N 1. P. 26 - 29.

155. Sarkar B.K., Sengupta P., Sarkar U.N. Surgical outcome in thymic tumors with myasthenia gravis after plasmapheresis--a comparative study.//Interact. Cardiovasc. Thorac. Surg. England, 2008. Vol. 7, N 6. P. 1007 - 1010.

156. Gajdos P., Chevret S., Toyka K. Plasma exchange for myasthenia gravis.//Cochrane database Syst. Rev. England, 2002. Vol. 2002, N 4. P. CD002275.

157. El-Bawab H. et al. Plasmapheresis before thymectomy in myasthenia gravis: routine versus selective protocols.//Eur. J. cardio-thoracic Surg. Off. J. Eur. Assoc. Cardio-thoracic Surg. Germany, 2009. Vol. 35, N 3. P. 392 - 397.

158. Reis T.A., Cataneo D.C., Cataneo A.J.M. Clinical usefulness of prethymectomy plasmapheresis in patients with myasthenia gravis: a systematic review and meta-analysis.//Interact. Cardiovasc. Thorac. Surg. England, 2019. Vol. 29, N 6. P. 867 - 875.

159. , Bucka C., Klingel R. A randomized and controlled study comparing immunoadsorption and plasma exchange in myasthenic crisis.//J. Clin. Apher. United States, 2011. Vol. 26, N 6. P. 347 - 355.

160. Yeh J.H., Chiu H.C. Comparison between double-filtration plasmapheresis and immunoadsorption plasmapheresis in the treatment of patients with myasthenia gravis.//J. Neurol. Germany, 2000. Vol. 247, N 7. P. 510 - 513.

161. Ipe T.S., Davis A.R., Raval J.S. Therapeutic Plasma Exchange in Myasthenia Gravis: A Systematic Literature Review and Meta-Analysis of Comparative Evidence.//Frontiers in neurology. Switzerland, 2021. Vol. 12. P. 662856.

162. Usmani A. et al. Excellent response to therapeutic plasma exchange in myasthenia gravis patients irrespective of antibody status.//J. Clin. Apher. United States, 2019. Vol. 34, N 4. P. 416 - 422.

163. Liu Z. et al. Predictors of extubation outcomes following myasthenic crisis.//J. Int. Med. Res. England, 2016. Vol. 44, N 6. P. 1524 - 1533.

164. Guptill J.T. et al. A retrospective study of complications of therapeutic plasma exchange in myasthenia.//Muscle Nerve. United States, 2013. Vol. 47, N 2. P. 170 - 176.

165. Mandawat A. et al. Outcome of plasmapheresis in myasthenia gravis: delayed therapy is not favorable.//Muscle Nerve. United States, 2011. Vol. 43, N 4. P. 578 - 584.

166. Gajdos P. et al. [Long-term effects of plasma exchange in myasthenia. Results of a randomized study].//Presse Med. France, 1983. Vol. 12, N 15. P. 939 - 942.

167. Ghimire A. et al. Assessing the comparative efficacy of plasmapheresis and Intravenous immunoglobulin in myasthenia gravis treatment: A systematic review and meta-analysis.//J. Clin. Neurosci. Off. J. Neurosurg. Soc. Australas. Scotland, 2024. Vol. 121. P. 1 - 10.

168. . Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to severe myasthenia gravis.//Artif. Organs. United States, 2001. Vol. 25, N 12. P. 967 - 973.

169. Ortiz-Salas P. et al. Human Immunoglobulin Versus Plasmapheresis in Guillain-Barre Syndrome and Myasthenia Gravis: A Meta-Analysis.//J. Clin. Neuromuscul. Dis. United States, 2016. Vol. 18, N 1. P. 1 - 11.

170. Yeh J.H., Chiu H.C. Plasmapheresis in myasthenia gravis. A comparative study of daily versus alternately daily schedule.//Acta Neurol. Scand. Denmark, 1999. Vol. 99, N 3. P. 147 - 151.

171. Zhang L. et al. Double filtration plasmapheresis benefits myasthenia gravis patients through an immunomodulatory action.//J. Clin. Neurosci. Off. J. Neurosurg. Soc. Australas. Scotland, 2014. Vol. 21, N 9. P. 1570 - 1574.

172. Liu C. et al. Efficacy and safety of double-filtration plasmapheresis treatment of myasthenia gravis: A systematic review and meta-analysis.//Medicine (Baltimore). United States, 2021. Vol. 100, N 17. P. e25622.

173. Liu J.-F. et al. Comparing the autoantibody levels and clinical efficacy of double filtration plasmapheresis, immunoadsorption, and intravenous immunoglobulin for the treatment of late-onset myasthenia gravis.//Ther. Apher. Dial. Off. peer-reviewed J. Int. Soc. Apher. Japanese Soc. Apher. Japanese Soc. Dial. Ther. Australia, 2010. Vol. 14, N 2. P. 153 - 160.

174. Yasuda M. et al. Immunoadsorption apheresis versus intravenous immunoglobulin therapy for exacerbation of myasthenia gravis.//Scand. J. Immunol. England, 2022. Vol. 95, N 2. P. e13122.

175. Wolfe G.I., Kaminski H.J., Cutter G.R. Randomized Trial of Thymectomy in Myasthenia Gravis.//The New England journal of medicine. United States, 2016. Vol. 375, N 20. P. 2006 - 2007.

176. Yang J. et al. Prognosis of thymectomy in myasthenia gravis patients with thymus hyperplasia.//Int. J. Neurosci. England, 2017. Vol. 127, N 9. P. 785 - 789.

177. Aljaafari D., Ishaque N. Thymectomy in myasthenia gravis: A narrative review//Saudi J. Med. Med. Sci. 2022. Vol. 10, N 2. P. 97 - 104.

178. Cataneo A.J.M., Felisberto G.J., Cataneo D.C. Thymectomy in nonthymomatous myasthenia gravis - systematic review and meta-analysis.//Orphanet J. Rare Dis. England, 2018. Vol. 13, N 1. P. 99.

179. Sanders D.B. et al. International consensus guidance for management of myasthenia gravis: Executive summary.//Neurology. United States, 2016. Vol. 87, N 4. P. 419 - 425.

180. England J.D. et al. Practice parameter: the evaluation of distal symmetric polyneuropathy: the role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review): Report of the American Academy of Neurology, the American Association of Neuromuscular and Elec//PM&R. Elsevier, 2009. Vol. 1, N 1. P. 14 - 22.

181. Madenci A.L. et al. The role of thymectomy in the treatment of juvenile myasthenia gravis: a systematic review.//Pediatr. Surg. Int. Germany, 2017. Vol. 33, N 6. P. 683 - 694.

182. . Results of surgical treatment for juvenile myasthenia gravis.//Neurologia. Spain, 2017. Vol. 32, N 3. P. 137 - 142.

183. Hennessey I.A.M. et al. Thymectomy for inducing remission in juvenile myasthenia gravis.//Pediatr. Surg. Int. Germany, 2011. Vol. 27, N 6. P. 591 - 594.

184. Tracy M.M., McRae W., Millichap J.G. Graded response to thymectomy in children with myasthenia gravis.//J. Child Neurol. United States, 2009. Vol. 24, N 4. P. 454 - 459.

185. Мызин А.В. et al. Опыт применения торакоскопической тимэктомии при миастении гравис у детей//Детская хирургия. ОАО "Издательство "Медицина", 2016. Vol. 20, N 3. P. 143 - 146.

186. Hess N.R. et al. Minimally invasive versus open thymectomy: a systematic review of surgical techniques, patient demographics, and perioperative outcomes.//Ann. Cardiothorac. Surg. China, 2016. Vol. 5, N 1. P. 1 - 9.

187. Ducci R.D. et al. Clinical follow-up of pregnancy in myasthenia gravis patients.//Neuromuscul. Disord. England, 2017. Vol. 27, N 4. P. 352 - 357.

188. Neykova K.K., Milanova M., Ignatov P.N. Myasthenia gravis and covid-19 in pregnancy: a review of the literature and case series report.//J. Matern. neonatal Med. Off. J. Eur. Assoc. Perinat. Med. Fed. Asia Ocean. Perinat. Soc. Int. Soc. Perinat. Obstet. England, 2022. Vol. 35, N 25. P. 8308 - 8316.

189. Pelufo-Pellicer A. et al. Fetal exposure to 3,4-diaminopyridine in a pregnant woman with congenital myasthenia syndrome.//Ann. Pharmacother. United States, 2006. Vol. 40, N 4. P. 762 - 766.

190. Ciafaloni E., Massey J.M. Myasthenia gravis and pregnancy.//Neurol. Clin. United States, 2004. Vol. 22, N 4. P. 771 - 782.

191. Draxler J. et al. Pregnancy in myasthenia gravis: a retrospective analysis of maternal and neonatal outcome from a large tertiary care centre in Germany.//Arch. Gynecol. Obstet. Germany, 2024. Vol. 310, N 1. P. 277 - 284.

192. Santeularia M.T. et al. Anestesia en 15 gestantes afectadas de miastenia grave//Rev. Esp. Anestesiol. Reanim. Ediciones Doyma, 1998. Vol. 45, N 2. P. 41 - 45.

193. Park Wyllie L. et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta analysis of epidemiological studies//Teratology. Wiley Online Library, 2000. Vol. 62, N 6. P. 385 - 392.

194. Hviid A., . Corticosteroid use during pregnancy and risk of orofacial clefts.//C. Can. Med. Assoc. J. = J. l'Association medicale Can. Canada, 2011. Vol. 183, N 7. P. 796 - 804.

195. Sharma U.R. et al. The positive effect of pregnancy in rheumatoid arthritis and the use of medications for the management of rheumatoid arthritis during pregnancy.//Inflammopharmacology. Switzerland, 2021. Vol. 29, N 4. P. 987 - 1000.

196. Thalluri V. et al. Exposure to corticosteroids in the first trimester is associated with an increased risk of urogenital congenital anomalies.//Hum. Reprod. England, 2022. Vol. 37, N 9. P. 2167 - 2174.

197. Benediktsson R. et al. Placental 11 beta-hydroxysteroid dehydrogenase: a key regulator of fetal glucocorticoid exposure.//Clin. Endocrinol. (Oxf). England, 1997. Vol. 46, N 2. P. 161 - 166.

198. Guillonneau M., Jacqz-Aigrain E. [Maternal corticotherapy. Pharmacology and effect on the fetus].//J. Gynecol. Obstet. Biol. Reprod. (Paris). France, 1996. Vol. 25, N 2. P. 160 - 167.

199. , Villiger P.M. Treatment of rheumatoid arthritis during pregnancy: present and future.//Expert Rev. Clin. Immunol. England, 2016. Vol. 12, N 9. P. 937 - 944.

200. Bermas B.L. Non-steroidal anti inflammatory drugs, glucocorticoids and disease modifying anti-rheumatic drugs for the management of rheumatoid arthritis before and during pregnancy.//Curr. Opin. Rheumatol. United States, 2014. Vol. 26, N 3. P. 334 - 340.

201. . Anti-inflammatory and immunosuppressive drugs and reproduction.//Arthritis Res. Ther. England, 2006. Vol. 8, N 3. P. 209.

202. Dao K.H., Bermas B.L. Systemic Lupus Erythematosus Management in Pregnancy.//Int. J. Womens. Health. New Zealand, 2022. Vol. 14. P. 199 - 211.

203. Birru Talabi M., Clowse M.E.B. Antirheumatic medications in pregnancy and breastfeeding.//Curr. Opin. Rheumatol. United States, 2020. Vol. 32, N 3. P. 238 - 246.

204. Odufalu F.-D. et al. Exposure to corticosteroids in pregnancy is associated with adverse perinatal outcomes among infants of mothers with inflammatory bowel disease: results from the PIANO registry.//Gut. England, 2022. Vol. 71, N 9. P. 1766 - 1772.

205. Gilhus N.E. Treatment considerations in myasthenia gravis for the pregnant patient//Expert Rev. Neurother. Taylor & Francis, 2023. Vol. 23, N 2. P. 169 - 177.

206. Norwood F. et al. Myasthenia in pregnancy: best practice guidelines from a UK multispecialty working group//J. Neurol. Neurosurg. Psychiatry. BMJ Publishing Group Ltd, 2014. Vol. 85, N 5. P. 538 - 543.

207. Ferrero S. et al. Myasthenia gravis: management issues during pregnancy//Eur. J. Obstet. Gynecol. Reprod. Biol. Elsevier, 2005. Vol. 121, N 2. P. 129 - 138.

208. Alami Z. et al. Pregnancy outcome following in utero exposure to azathioprine: A French comparative observational study.//Therapie. France, 2018. Vol. 73, N 3. P. 199 - 207.

209. Assudani L., Notwani A. Myasthenia gravis in pregnancy: a case report//Int J Reprod Contraception, Obs. Gynecol. 2023. Vol. 12, N 1. P. 264 - 267.

210. Massey J.M., De Jesus-Acosta C. Pregnancy and myasthenia gravis//Contin. Lifelong Learn. Neurol. LWW, 2014. Vol. 20, N 1. P. 115 - 127.

211. Sifontis N.M. et al. Pregnancy outcomes in solid organ transplant recipients with exposure to mycophenolate mofetil or sirolimus.//Transplantation. United States, 2006. Vol. 82, N 12. P. 1698 - 1702.

212. Kim M., Rostas S., Gabardi S. Mycophenolate fetal toxicity and risk evaluation and mitigation strategies//Am. J. Transplant. Elsevier, 2013. Vol. 13, N 6. P. 1383 - 1389.

213. Lloyd M.E. et al. The effects of methotrexate on pregnancy, fertility and lactation//Qjm. Oxford University Press, 1999. Vol. 92, N 10. P. 551 - 563.

214. Enns G.M. et al. Apparent cyclophosphamide (cytoxan) embryopathy: a distinct phenotype?//Am. J. Med. Genet. Wiley Online Library, 1999. Vol. 86, N 3. P. 237 - 241.

215. Harward L.E. et al. The impact of cyclophosphamide on menstruation and pregnancy in women with rheumatologic disease//Lupus. SAGE Publications Sage UK: London, England, 2013. Vol. 22, N 1. P. 81 - 86.

216. Weimer L.H. Neuromuscular disorders in pregnancy.//Handb. Clin. Neurol. Netherlands, 2020. Vol. 172. P. 201 - 218.

217. Gilbert A.L., Prasad S., Mallery R.M. Neuro-Ophthalmic Disorders in Pregnancy.//Neurol. Clin. United States, 2019. Vol. 37, N 1. P. 85 - 102.

218. Blichfeldt-Lauridsen L., Hansen B.D. Anesthesia and myasthenia gravis.//Acta Anaesthesiol. Scand. England, 2012. Vol. 56, N 1. P. 17 - 22.

219. Abel M., Eisenkraft J.B. Anesthetic implications of myasthenia gravis.//Mt. Sinai J. Med. United States, 2002. Vol. 69, N 1 - 2. P. 31 - 37.

220. Baraka A. Onset of neuromuscular block in myasthenic patients.//British journal of anaesthesia. England, 1992. Vol. 69, N 2. P. 227 - 228.

221. Sungur Z., . Anaesthesia for thymectomy in adult and juvenile myasthenic patients.//Curr. Opin. Anaesthesiol. United States, 2016. Vol. 29, N 1. P. 14 - 19.

222. van den Bersselaar L.R. et al. European Neuromuscular Centre consensus statement on anaesthesia in patients with neuromuscular disorders.//Eur. J. Neurol. England, 2022. Vol. 29, N 12. P. 3486 - 3507.

223. Cata J.P. et al. Myasthenia Gravis and Thymoma Surgery: A Clinical Update for the Cardiothoracic Anesthesiologist.//J. Cardiothorac. Vasc. Anesth. United States, 2019. Vol. 33, N 9. P. 2537 - 2545.

224. Spasojevic I. et al. SPECIFIC FEATURES OF ANESTHESIA IN PATIENTS WITH MYASTHENIA GRAVIS.//Med. Pregl. Serbia, 2016. Vol. 69, N 9 - 10. P. 305 - 311.

225. Sungur Ulke Z. et al. Rocuronium and sugammadex in patients with myasthenia gravis undergoing thymectomy//Acta Anaesthesiol. Scand. Wiley Online Library, 2013. Vol. 57, N 6. P. 745 - 748.

226. Carron M., De Cassai A., Linassi F. Sugammadex in the management of myasthenic patients undergoing surgery: beyond expectations.//Annals of translational medicine. China, 2019. Vol. 7, N Suppl 8. P. S307.

227. Mouri H. et al. Effect of Sugammadex on Postoperative Myasthenic Crisis in Myasthenia Gravis Patients: Propensity Score Analysis of a Japanese Nationwide Database.//Anesth. Analg. United States, 2020. Vol. 130, N 2. P. 367 - 373.

228. Fernandes H.D.S. et al. Failure of reversion of neuromuscular block with sugammadex in patient with myasthenia gravis: case report and brief review of literature.//BMC Anesthesiol. England, 2019. Vol. 19, N 1. P. 160.

229. Della Rocca G. et al. Propofol or sevoflurane anesthesia without muscle relaxants allow the early extubation of myasthenic patients.//Can. J. Anaesth. United States, 2003. Vol. 50, N 6. P. 547 - 552.

230. Fujita Y. et al. Estimation of the success rate of anesthetic management for thymectomy in patients with myasthenia gravis treated without muscle relaxants: a retrospective observational cohort study.//J. Anesth. Japan, 2015. Vol. 29, N 5. P. 794 - 797.

231. O'Flaherty D. et al. Total intravenous anesthesia with propofol for transsternal thymectomy in myasthenia gravis.//J. Clin. Anesth. United States, 1992. Vol. 4, N 3. P. 241 - 244.

232. Hien V. Van, Tu N.H., Thu N.D. Propofol TCI or sevoflurane anesthesia without muscle relaxant for thoracoscopic thymectomy in myasthenia gravis patients: a prospective, observational study.//BMC Anesthesiol. England, 2023. Vol. 23, N 1. P. 349.

233. Burgess F.W., Wilcosky B.J. Thoracic epidural anesthesia for transsternal thymectomy in myasthenia gravis.//Anesth. Analg. United States, 1989. Vol. 69, N 4. P. 529 - 531.

234. Yarom N. et al. Dental management of patients with myasthenia gravis: a literature review.//Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. United States, 2005. Vol. 100, N 2. P. 158 - 163.

235. Prabhu S.S. et al. Anesthetic considerations for a patient with myasthenia gravis undergoing deep sedation in an outpatient oral surgery setting.//Journal of dental anesthesia and pain medicine. Korea (South), 2019. Vol. 19, N 1. P. 67 - 72.

236. Corrado B., Giardulli B., Costa M. Evidence-based practice in rehabilitation of myasthenia gravis. A systematic review of the literature//J. Funct. Morphol. Kinesiol. MDPI, 2020. Vol. 5, N 4. P. 71.

237. Nelke C. et al. Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients.//J. Neuroinflammation. England, 2022. Vol. 19, N 1. P. 89.

238. Wang Y. et al. Independent risk factors for in-hospital outcome of myasthenic crisis: a prospective cohort study.//Ther. Adv. Neurol. Disord. England, 2024. Vol. 17. P. 17562864241226744.

239. Grob D. et al. Lifetime course of myasthenia gravis.//Muscle Nerve. United States, 2008. Vol. 37, N 2. P. 141 - 149.

240. Djelmis J. et al. Myasthenia gravis in pregnancy: report on 69 cases.//Eur. J. Obstet. Gynecol. Reprod. Biol. Ireland, 2002. Vol. 104, N 1. P. 21 - 25.

241. Eden R.D., Gall S.A. Myasthenia gravis and pregnancy: a reappraisal of thymectomy.//Obstet. Gynecol. United States, 1983. Vol. 62, N 3. P. 328 - 333.

242. Щербакова Н.И. et al. Неотложные состояния при миастении//Неотложные состояния в неврологии. 2011. P. 92 - 100.

243. Claytor B., Cho S.-M., Li Y. Myasthenic crisis.//Muscle Nerve. United States, 2023. Vol. 68, N 1. P. 8 - 19.